Zacks Investment Research Upgrades Transenterix (TRXC) to Hold
Zacks Investment Research upgraded shares of Transenterix (NYSEAMERICAN:TRXC) from a sell rating to a hold rating in a research report report published on Tuesday morning.
According to Zacks, “TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States. “
A number of other brokerages have also commented on TRXC. Ladenburg Thalmann Financial Services set a $5.00 price objective on shares of Transenterix and gave the company a buy rating in a research report on Friday, October 20th. Stifel Nicolaus reaffirmed a buy rating and set a $4.00 price objective (up previously from $3.75) on shares of Transenterix in a research report on Monday, October 30th. Finally, BTIG Research reaffirmed a hold rating on shares of Transenterix in a research report on Monday, December 18th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Transenterix has a consensus rating of Hold and a consensus target price of $2.61.
Transenterix (NYSEAMERICAN:TRXC) last released its earnings results on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.09). Transenterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%.
In related news, CFO Joseph P. Slattery sold 529,609 shares of the stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $2.80, for a total value of $1,482,905.20. Following the completion of the transaction, the chief financial officer now owns 440,974 shares of the company’s stock, valued at $1,234,727.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph P. Slattery sold 333,000 shares of the stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $2.93, for a total transaction of $975,690.00. Following the completion of the transaction, the chief financial officer now directly owns 440,974 shares of the company’s stock, valued at approximately $1,292,053.82. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Transenterix stock. Ladenburg Thalmann Financial Services Inc. grew its position in shares of Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 79,150 shares of the medical instruments supplier’s stock after buying an additional 37,000 shares during the quarter. Ladenburg Thalmann Financial Services Inc. owned approximately 0.05% of Transenterix worth $113,000 as of its most recent filing with the Securities and Exchange Commission.
TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2018/01/24/zacks-investment-research-upgrades-transenterix-trxc-to-hold.html.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.